Recce Pharmaceuticals Ltd.ASX: RCE

Independent Review of Indonesian Phase 3 R327G Trial Data

· Issued by Recce Pharmaceuticals Ltd. via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Patient recruitment and dosing will continue while the DMC conducts its review, with recommendations expected after their meeting. The company will provide updates following the DMC's formal recommendations, which may influence the trial's progression.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement Independent Data Monitoring Committee to Review Phase 3 Clinical Trial Data of Recce’s Topical Gel for Diabetic Foot Ulcer Infections Highlights: • Review of the blinded data indicates strong efficacy across the study population ® • RECCE 327 Gel (R327G) continues to...

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

Later from Recce Pharmaceuticals

All Recce Pharmaceuticals news releases